Stocksigma LogoStocksigma Logo

Shukra Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

■ Revenue: 4,420 (+652.1% YoY | +87.9% QoQ) ■ EBITDA: 1,870 (Loss to Profit YoY | -2.3% QoQ) ■ EBITDA Margin (%): 42.3 (Loss to Profit YoY | -3907 bps QoQ)

Shukra Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

Shukra Pharmaceuticals Ltd · Outcome · 05 Nov 2026, 2:10 am

Shukra Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 4,420 (+652.1% YoY | +87.9% QoQ) ■ EBITDA: 1,870 (Loss to Profit YoY | -2.3% QoQ) ■ EBITDA Margin (%): 42.3 (Loss to Profit YoY | -3907 bps QoQ) ■ PAT: 1,271 (+434.5% YoY | -1.9% QoQ) ■ EPS (INR): 0.29 (+480.0% YoY | -3.3% QoQ) Shukra Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) Segmental Performance Pharmaceutical segment ■ Revenue: 3,227 (+325.2% YoY | +34.1% QoQ) ■ EBIT: 1,506 (+3016.3% YoY | -19.0% QoQ) ■ EBIT Margin (%): 46.7 (+4031 bps YoY | -3062 bps QoQ) Medtech segment ■ Revenue: 1,251 ■ EBIT: 310 ■ EBIT Margin (%): 24.8

Original exchange filing (PDF)

More announcements from Shukra Pharmaceuticals Ltd

All Shukra Pharmaceuticals Ltd announcements